Media stories about R1 RCM (NASDAQ:RCM) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. R1 RCM earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media coverage about the financial services provider an impact score of 46.2682446784917 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

R1 RCM (NASDAQ:RCM) opened at $4.29 on Thursday. R1 RCM has a 12-month low of $2.02 and a 12-month high of $4.37.

A number of research firms recently weighed in on RCM. Zacks Investment Research upgraded R1 RCM from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Robert W. Baird reiterated a “hold” rating and set a $5.00 price objective on shares of R1 RCM in a research report on Tuesday, September 26th.

COPYRIGHT VIOLATION NOTICE: This story was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at

About R1 RCM

R1 RCM Inc, formerly Accretive Health, Inc, is a provider of revenue cycle management (RCM) and physician advisory services (PAS) to healthcare providers. The Company is engaged in providing management services of revenue cycle operations for the United States-based hospitals and other medical services providers.

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with Analyst Ratings Network's FREE daily email newsletter.